ABCL vs PNTG

ABCL exhibits severe financial distress according to the Piotroski F-Score (1/9), indicating weak operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics—particularly a -194.88% profit margin and -14.47% ROE—highlight deep operational inefficiencies. Despite a 788.2% YoY revenue growth and strong earnings surprise history (average +30.86% over last 4 quarters), the company remains unprofitable and carries significant valuation risk. The current price of $3.49 trades at a steep 14.08 Price/Sales ratio, far exceeding sector averages, suggesting speculative pricing. Analysts' target price of $9.17 implies strong upside potential, but this is based on unproven profitability and high risk.

PNTG exhibits a stable financial foundation with a Piotroski F-Score of 6/9 and explosive growth metrics, though it currently trades at a premium to its Graham Number ($13.43) and Intrinsic Value ($24.78). The company is experiencing massive YoY revenue and earnings growth exceeding 53%, which justifies the current P/E expansion and the significant drop in Forward P/E (19.39). While the valuation is stretched relative to defensive benchmarks, the strong analyst consensus and operational momentum suggest further upside toward the $38.17 target. However, the narrow profit margins and heavy reliance on Medicare reimbursement remain primary headwinds.